Carisma Therapeutics Inc [NASDAQ: CARM] stock went on a downward path that fall over -5.70% on Monday, amounting to a one-week price decrease of less than -8.90%.
Over the last 12 months, CARM stock dropped by -48.66%. The one-year Carisma Therapeutics Inc stock forecast points to a potential upside of 78.0. The average equity rating for CARM stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $8.98 million, with 41.79 million shares outstanding and 21.80 million shares in the current float. Compared to the average trading volume of 13.80M shares, CARM stock reached a trading volume of 27916906 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Carisma Therapeutics Inc [CARM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CARM shares is $1.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CARM stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Robert W. Baird have made an estimate for Carisma Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 12, 2024. The new note on the price target was released on December 10, 2024, representing the official price target for Carisma Therapeutics Inc stock. Previously, the target price had yet another raise to $6, while BTIG Research analysts kept a Buy rating on CARM stock.
CARM Stock Performance Analysis:
Carisma Therapeutics Inc [CARM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.90. With this latest performance, CARM shares dropped by -33.23% in over the last four-week period, additionally sinking by -46.38% over the last 6 months – not to mention a drop of -48.66% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CARM stock in for the last two-week period is set at 30.82, with the RSI for the last a single of trading hit 0.0253, and the three-weeks RSI is set at 0.0340 for Carisma Therapeutics Inc [CARM]. The present Moving Average for the last 50 days of trading for this stock 0.3415, while it was recorded at 0.2266 for the last single week of trading, and 0.4078 for the last 200 days.
Insight into Carisma Therapeutics Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Carisma Therapeutics Inc [CARM] shares currently have an operating margin of -428.26% and a Gross Margin at 69.35%. Carisma Therapeutics Inc’s Net Margin is presently recorded at -458.60%.
Carisma Therapeutics Inc (CARM) Capital Structure & Debt Analysis
Carisma Therapeutics Inc (CARM) Efficiency & Liquidity Metrics
Carisma Therapeutics Inc (CARM) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Carisma Therapeutics Inc. (CARM) effectively leverages its workforce, generating an average of -$1073478.26 per employee. The company’s liquidity position is robust, with a Current Ratio of 0.48% and a Quick Ratio of 0.48%, indicating strong ability to cover short-term liabilities.
CARM Stock EPS
With the latest financial reports released by the company, Carisma Therapeutics Inc posted -0.31/share EPS, while the average EPS was predicted by analysts to be reported at -0.36/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.05. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CARM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Carisma Therapeutics Inc go to 32.95%.
Carisma Therapeutics Inc [CARM] Institutonal Ownership Details
There are presently around $26.32%, or 36.44%% of CARM stock, in the hands of institutional investors. The top three institutional holders of CARM stocks are: VANGUARD GROUP INC with ownership of 1.45 million shares, which is approximately 3.4861%. TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, holding 1.25 million shares of the stock with an approximate value of $$1.9 million in CARM stocks shares; and TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, currently with $$1.28 million in CARM stock with ownership which is approximately 2.0269%.
